CN1748779A - Medicinal composition for treating chronic prostatitis and its preparation method and use - Google Patents

Abstract

The medicine composition for treating chronic prostatitis consists of curcuma 4-6 weight portions, amur barbery peel 3-5 weight portions, emblic 7-9 weight portions and puncture vine 7-9 weight portions. The medicine composition is prepared through improved technological process and has new preparation form and new indication, determined curative effect in treating chronic prostatitis, and raised bactericidal effect in treating urethritis. The preparation process has raised quality standard, increased qualitative and quantitative discrimination method, raised controllability and stable preparation.

Description

A kind of pharmaceutical composition for the treatment of chronic prostatitis and its production and use

Technical field

The present invention relates to a kind of pharmaceutical composition for the treatment of chronic prostatitis, particularly, is to be the prostatitic pharmaceutical composition of treatment that feedstock production forms with Chinese medicine, good medicine, belongs to the field of Chinese medicines.

Background technology

Prostatitis is divided into acute prostatitis and chronic prostatitis, according to its cause of disease difference, is divided into six classes again: the non-specific bacterial prostatitis of I type, divide urgency and chronic prostatitis again; The special property sent out of II type nonbacterial prostatitis claims prostatosis again; III type specificity prostatitis, the prostatitis that causes as gonococcus, syphilis, tulase, fungus, infusorian etc.; IV type nonspecific granulomatous prostatitis; V-type prostatodynia and congestion of prostate; The VI type other: the prostate adenitis that causes as virus, mycoplasma, chlamydia infection.Acute prostatitis is the acute prostatitis disease that is caused by bacterial infection.Acute prostatitis can have aversion to cold, heating, General Symptoms such as weak; Local symptom is that perineum or suprapubic region territory have the weight sense, increases the weight of when sitting or defecation, and locates radiation to waist, lower abdomen, back and thigh etc., if there is microabscess to form, the pain increased and can not defecation; Urethral symptom has burn feeling, urgent micturition, frequent micturition when urinating, can be with terminal hematuria or the urethra purulent secretion of urinating; The rectum symptom is rectum distension, just urgency and defecate feeling, and urethral orifice can flow out white secretions during stool.Its pathological change mainly is with polymorphonuclear leukocyte infiltration, destroys the prostate body of gland, or prostate conduit and epithelium thereof and contiguous between matter be its characteristics, be by due to the bacterial infection.

Chronic prostatitis is divided into bacterial prostatitis and non-bacterial.The former is often changed by acute prostatitis; Latter's cause of disease complexity, good sending out in person between twenty and fifty be it is generally acknowledged, often hyperemia, edema are its important pathogenic factors to the prostate that a variety of causes causes repeatedly or continuously.The pathological change of chronic prostatitis is that acinus, gland and a matter are inflammatory reaction, apocyte, lymphocyte, plasma cell and macrophages infiltration and connective tissue proliferation are arranged, the necrosis region fibrosis, the glandular tube tube chamber narrows down, or tubule is by pus cell and the expansion of last cell obstruction causing acinus, acinus expands then that body of gland presents pliable and tough sensation, and last gland structure destroys shrinkage and forms fibrosis.Prostate becomes the quality hardening because of fibroid or dwindles, and fibrosis can involve the back urethra when serious, makes the neck of bladder sclerosis.Seminal vesicle and ampulla of deferent duct also have proliferation of fibrous tissue, and parietal layer thickens, and it is narrow that seminal vesicle and ejaculatory duct opening can cause fibrosis.

At present, the treatment prostate divides western medicine, treatment by Chinese herbs, and its western medicines in treatment is with antibiotic, Comprehensive Treatment such as support to suit the medicine to the illness.Select effective antibiotic (comprising the special medicine thing); Clinical about 40% patient's combating microorganisms medicine treatment chronic nonbacterial prostatitis that shows has certain effect.So the antimicrobial drug treatment occupies suitable critical role in the chronic prostatitis treatment.And because prostate giving drugs into nose dynamic (dynamical) particularity of generation should be selected fat-solubility, dissociation constant (PKa) height, low with plasma protein binding rate, reach the suitable beneficial drug of pH and enter prostata tissue, the while is has a broad antifungal spectrum again, is difficult for producing drug-fast kind.At present commonly used have Tetracyclines, because the barrier action of prostate lipid envelope, most of antibacterials are difficult to enter and reach effective Mlc in the prostate, have only fat-soluble high alkalescent medicine; Combine less the medicine that the degree of dissociation is high with plasma protein; Just might bring into play curative effect preferably to the medicine that prostate adipose membrane dispersivity is good, the medicine that meets these conditions has trimethoprim (TMP), bactrim (including trimethoprim (TMP)), erythromycin, lincomycin, rifampicin, norfloxacin etc.In addition, ofloxacin, minocycline, thyrite top grade curative effect of medication are better.In addition, α receptor blocking agent, anti-inflammation analgesic etc. all can be treated prostatitis; Above-mentioned Western medicine all easily produces drug resistance, and toxic and side effects is big, because first pass effect, liver metabolism, the inaccessible patient part of medicine.

Because the special physiological structure of prostate and to the selectivity of medicine, have relatively high expectations, those can not just be of no curative effect to prostatitis by the antibacterials of prostate lipid envelope, therefore, the most antibiotics except that said medicine does not all have therapeutical effect to prostatitis.

The treatment by Chinese herbs prostatitis has blood circulation promoting and blood stasis dispelling, dredge the meridian passage, depressed liver-energy dispersing and QI regulating, heat-clearing and toxic substances removing, dampness removing diuresis effect.According to different symptoms, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.At present, the Chinese medicine that is usually used in chronic prostatitis has QIANLIEKANG PIAN, capsule (Kang Enbei group) (be pure Pollen Preparations, have treatment and health care double effects); Prostatitis return of spring capsule (rejuvenate, and it is treating stranguria to invigorate blood circulation, heat-clearing and toxic substances removing by this product kidney tonifying.Diseases such as the frequent micturition that is used for chronic prostatitis and causes by prostatitis, urgent micturition, Urethra astringent pain, stranguria with turbid discharge, hyposexuality, impotence and premature ejaculation), QIANLIETONG PIAN (heat-clearing and toxic substances removing, clear dampness removing is turbid, vital energy regualting and blood circulation-promoting, anti-inflammatory analgetic, blood stasis dispelling is treating stranguria.Be used for acute prostatitis, prostatic hyperplasia.), prostatitis capsule for eliminating (clearing away heat-damp and promoting diuresis.Be used for the burnt damp-heat syndrome person of prostatitis subordinate, disease is seen: frequent micturition, urgent micturition, the puckery pain of urine, dribbling urination not to the utmost, soreness of the waist and knees etc.), the prostate disease granule (tonify Qi of the kidney, and blood stasis dispelling is treating stranguria by this product.It is two empty to cure mainly the kidney spleen, qi depression to blood stasis, prostatic hyperplasia, chronic prostatitis), brilliant pearl 'Qianlielongbitong ' capsule (QI invigorating warming YANG, activating blood and promoting diuresis.Be used for the difficulty in urination due to the blood stasis due to renal deficiency, disease is seen frequent micturition, urinates in delaying, require great effort dribble of urine, soreness of the waist and knees; Prostatic hyperplasia is seen above-mentioned patient.), the course of treatment of this type of disease of Chinese traditional treatment is long, but carry out diagnosis and prescription, have transfer human body self exempt from service function, characteristics completely sterilize, because the Chinese patent medicine material combination is based on Chinese medical theory, the selection of material medicine has determined different diseases and disease, the prescription difference, raw material consumption difference, at indication also have any different.

Tibetan medicine standard WS ₃-BC-0304-95, " SIWEI JIANGHUANG TANGSAN ", disclosing writes out a prescription is: Rhizoma Curcumae Longae 15g, Radix Berberidis Amurensis 12.5g, Fructus Phyllanthi 25g, Fructus Tribuli 25g, and method for making: above four flavors, be ground into coarse powder, sieve, mixing, promptly.Function cures mainly: heat clearing away, diuresis.Be used for urethritis, frequent micturition, urgent micturition.

The traditional Chinese medical science thinks that the etiology and pathogenesis of urethritis is that damp-heat accumulation, the stasis of blood hinder due to the vessels of the uterus.Therefore, urethritis is compared with prostatitis, and the cause of disease, pathogenesis are all inequality, and the method for treatment rule of treatment is also inequality, does not still have " SIWEI JIANGHUANG TANGSAN " at present and treats prostatitic relevant report.

Summary of the invention

Practice by the inventor, technical scheme of the present invention has provided the new purposes of " SIWEI JIANGHUANG TANGSAN ", promptly provide a kind of treatment prostatitic pharmaceutical composition, another technical scheme of the present invention has provided this preparation of drug combination method, and it is former the technology dosage form of " SIWEI JIANGHUANG TANGSAN " changes.

The invention provides a kind of by containing the purposes of pharmaceutical composition in the medicine of preparation treatment chronic prostatitis that the following weight proportion raw material is prepared from:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis.

Further, it is to be prepared from by the following weight proportion raw material:

5 parts in Rhizoma Curcumae Longae, 4 parts of Radix Berberidis Amurensis, 8 parts of Fructus Phyllanthis, 8 parts of Fructus Tribulis.

The invention provides and a kind ofly be: the pharmaceutical composition of the treatment chronic prostatitis that the feedstock production of 4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis forms by containing weight proportion.

Described pharmaceutical composition is that the pharmaceutical composition by chronic prostatitis is the medicament that is prepared from by the following weight proportion raw material:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis.

Further, it is the medicament that is prepared from by the following weight proportion raw material:

5 parts in Rhizoma Curcumae Longae, 4 parts of Radix Berberidis Amurensis, 8 parts of Fructus Phyllanthis, 8 parts of Fructus Tribulis.

Pharmaceutical composition of the present invention is that the water extract by the ethanol extraction of Rhizoma Curcumae Longae, Radix Berberidis Amurensis and Fructus Phyllanthi, Fructus Tribuli is mixed into active component, adds the medicament that acceptable accessories or complementary composition are prepared from.

Wherein, described medicament is: pill, powder, tablet, capsule, granule, oral liquid, injection.

Wherein, every capsules contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 2.4mg; Every in tablet contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 0.6mg (in 12 slices/time); Every of pill contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 0.12mg (in 60/time); Every 10g powder contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 1.2mg (in 60g/ time); Every 10ml oral liquid contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 1.2mg (in 60ml/ time).

The present invention also provides this preparation of drug combination method, and it comprises the steps:

A, take by weighing and contain the following weight proportion raw material:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis;

B, Rhizoma Curcumae Longae, Radix Berberidis Amurensis ethanol extraction, concentration of alcohol are 60%～95%, reclaim ethanol, get extracting solution;

C, Fructus Phyllanthi, Fructus Tribuli are adopted water extract, ethanol is refining, and concentration of alcohol 50～90% reclaims ethanol, extracting solution;

D, b step gained extracting solution is mixed with c step extracting solution, add acceptable accessories or complementary composition, be prepared into preparation pharmaceutically commonly used.

The present invention also provides the purposes of this pharmaceutical composition in the medicine of preparation treatment urethritis.

Drug regimen raw material of the present invention is made up of four Chinese medicine materials such as Rhizoma Curcumae Longae, Radix Berberidis Amurensis, Fructus Phyllanthi, Fructus Tribulis.Rhizoma Curcumae Longae wherein: the dry rhizome of zingiberaceous plant Rhizoma Curcumae Longae.RHIZ0MA CURCUMAE LONGAE; Radix Berberidis Amurensis: Berberidaceae plant kansu barberry bark BERBERIS KANSUENSIS SCHNEID and belong to the dry skin of various plants together; Fructus Phyllanthi: the dry mature fruit of euphorbia plant Fructus Phyllanthi, FRUCTUS PHYLLANTHI; Fructus Tribuli: the dry mature fruit of zygophyllaceae plant Fructus Tribuli, FRUCTUS TRIBULI.

Prostatitis or because of throwing off restraint the pungent savoury of food, transporting and transforming function of the spleen and stomach is not normal, retention of damp-heat in the interior; Or because of experiencing epidemic disease poison, damp-heat flowing down to the urinary bladder; Or fire is prosperous partially mutually, and sexual behavior is unusual, loses smart hyperemia etc.Damp and hot symptom such as clinical common frequent micturition, urgent micturition, turbid urine, red tongue with yellow fur are thick.Prostatitis is because damp invasion of lower energizer easily causes qi depression to blood stasis, the vexed bloated pain of clinical also common perineum, testis, spermatic cord, waist sacrum distending pain.Fructus Phyllanthi in the side (the Tibetan medicine name: feel as drawing sour in the mouth, cool in nature, sharp) clearing away heat and cooling blood, be mainly used in Baconic's disease, red crust disease, liver-gallbladder disease, frequent micturition." Chinese pharmacopoeia claims its nature and flavor: sweet, sour, puckery, cool.Attach to the lung and stomach meridians.Function with cure mainly: clearing away heat and cooling blood is used for the heat in blood blood stasis.Rhizoma Curcumae Longae (the Tibetan medicine name: bitter in the mouth, suffering forever, cool in nature) detoxifcation, putrefaction removing.Be mainly used in alimentary toxicosis, pestilence disease, furuncle carbuncle, hemorrhoid." Chinese pharmacopoeia claims its nature and flavor: hot, bitter, warm.Function with cure mainly: removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia.Be used for the costa sternales twinge, amenorrhea, lump in the abdomen, rheumatism shoulder arm pain, tumbling and swelling.The prostatitis course of disease is for a long time continuous, and prolonged illness is just being hindered." interior warp " day: " infirmity person is arranged, urination for several ten times a day, this deficiency is also." the prostatitis later stage suffers from a deficiency of the kidney, gasification not as good as the state all, negative and positive of qi and blood decreases partially, the functioning of bladder malfunction, water-damp retention, thus clinical visible spiritlessness and weakness, soreness of waist and knee joint, even seminal emission, premature ejaculation, sterile etc.Fructus Tribuli (the Tibetan medicine name: match agate sweet in the mouth, warm in nature slightly poisonous) foster kidney, diuretic.Be mainly used in the waist renal cold and be used for card, cold grand disease, edema, dysuria, arthralgia chiefly caused by damp pathogen, psoriasis.Fructus Tribuli is one of five grains.Compatibilities such as this medicine and Fructus Malvae, Eriocheir sinensis are made three ingredient tribulus fruit soup and are loose, and cure mainly urine retention.Compatibilities such as this medicine and Moschus, Fructus Phyllanthi Mumiyah-asil are made four flavor Fructus Tribuli soup and are loose, and cure mainly hot urine retention.Compatibilities such as this medicine and Herba pleurospermi thomsonii, Radix Mirabilis himalaicae, Fructus Hippophae cream are made seven flavor Fructus Tribuli balls, cure mainly kidney pain in the lumbar region pain, renal cold, frequent micturition." Chinese pharmacopoeia claims its nature and flavor: hot, bitter, tepor; Slightly poisonous.Return Liver Channel.Function with cure mainly: the suppressing the hyperactive liver resolving depression, promoting blood circulation by removing wind makes eye bright, and is antipruritic.It is dizzy to be used to have a headache, distending pain in the chest and hypochondrium, conjunctival congestion cataracta, rubella pruritus.Main active is a steroidal saponin, and the pharmacological research proof has blood pressure lowering, diuresis.Radix Berberidis Amurensis (good medicine name: outstanding star bitter in the mouth, cool in nature, rough) heat clearing away, detoxifcation, antidiarrheal makes eye bright.Be mainly used in the diffusion of poisoning, grasserie, conjunctivitis redness, cataracta, sarcoma, aphtha, pharyngolaryngitis, diarrhoea, urinary tract infection, dysurea, hematuria, nebulousurine.Compatibilities such as this medicine and Piper longum, Fructus Phyllanthi, Radix Glycyrrhizae are made eight flavor Radix Berberidis Amurensis and are loose, and cure mainly urinary tract infection, dysurea, nebulousurine, hematuria, spermatorrhea.Claim its nature and flavor in " Tibetan medicine standard ": hardship, cold.Function with cure mainly: heat-clearing and toxic substances removing, dampness.Be used for dysentery, urinary tract infection, nephritis and furuncle, conjunctivitis etc.The main active of Radix Berberidis Amurensis is protoberberine type (quaternary amines) alkaloid, mainly comprise berberine (Berberine), palmatine (Paimatine), jateorhizine (Jatrorrhizine) etc., pharmacological research shows that Radix Berberidis Amurensis has and eases the pain and inflammatory phenomena.

Modern medicine study thinks that prostatitis mostly is coccus and bacillus mixed infection greatly.Radix Berberidis Amurensis has significantly antibiotic, antiinflammatory action, and dysentery bacterium, staphylococcus and streptococcus etc. are had the obvious suppression effect.Fructus Phyllanthi major physiological active component is a tannin, effects such as that tannin has is significantly antibiotic, antiinflammatory, anti-cell poison, mutation, pharmacology and pharmacodynamic study result show, Fructus Phyllanthi all has certain inhibitory action to coccuses such as golden yellow, Bacillus typhi, streptococcus, escherichia coli and Candida albicans, the inflammation that experimental peritonitis, Oleum Tiglii mixing proinflammatory agent are caused has certain antiinflammatory action, and cotton balls inflammation cotton balls granulation hyperplasia is had inhibition trend.Curcumin is the major physiological active component of Rhizoma Curcumae Longae, and pharmacological research shows that curcumin has good anti-inflammatory activity and analgesic activity.

By the pharmacodynamics test explanation, pharmaceutical composition of the present invention changes by technology, dosage form, increased new indication, sharp clearly bladder is arranged, the heat clearing and blood stasis dispersing collateral dredging, the kidney warming controlling nocturnal emission with astringent drugs effect, treatment chronic prostatitis determined curative effect, aspect antibiotic, sterilization, aspect the treatment urethritis, drug effect improves, and has improved quality standard, increase qualitative, quantitative identification method, controllability improves, preparation stabilization, and material medicine all derives from the high altitude localities, the biological activity of medicine is higher relatively, provides a kind of new selection for clinical.

Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.

The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.

The specific embodiment

The preparation of embodiment 1 medicine capsule of the present invention

1, prescription

Rhizoma Curcumae Longae 290g Radix Berberidis Amurensis 242g Fructus Phyllanthi 484g Fructus Tribuli 484g

Adjuvant: micropowder silica gel 40g calcium hydrogen phosphate 40g dextrin an amount of (about 40g)

Make 1000 of capsules, every dress 0.4g

2, method for making

More than four flavors, get Rhizoma Curcumae Longae, Radix Berberidis Amurensis is ground into coarse powder, adds 85% alcohol reflux 3 times, add for the first time 10 times of amount ethanol, second and third time adds 6 times of amount ethanol, each 1 hour, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste of relative density 1.20 (60 ℃ of heat are surveyed), 60 ℃ of drying under reduced pressure add each 20g of calcium hydrogen phosphate and dextrin respectively, pulverize, mixing, standby; Other gets, and Fructus Phyllanthi is broken into fragment and Fructus Tribuli decocts with water 3 times, adds 12 times of water gagings at every turn, decocted 1 hour, collecting decoction filters, filtrate is concentrated into relative density 1.20 (60 ℃ heat survey), adds ethanol, makes to contain the alcohol amount and reach 70%, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol, 80 ℃ of drying under reduced pressure of concentrated solution add micropowder silica gel 20g to thick paste, 80 ℃ of drying under reduced pressure are pulverized mixing.Get above-mentioned two kinds of dry extracts, add calcium hydrogen phosphate, each 20g of micropowder silica gel, dextrin is adjusted total amount in right amount to 400g, and mixing incapsulates, and makes 1000, promptly.

The preparation of embodiment 2 drug particles of the present invention

1, prescription: Rhizoma Curcumae Longae 348g Radix Berberidis Amurensis 302.5g Fructus Phyllanthi 484g Fructus Tribuli 484g Semen Plantaginis 174g

Adjuvant: an amount of dextrin of an amount of calcium hydrogen phosphate of micropowder silica gel is an amount of

Make granule.

2, method for making

More than four flavors, get Rhizoma Curcumae Longae, Radix Berberidis Amurensis is ground into coarse powder, adds 85% alcohol reflux 3 times, add for the first time 10 times of amount ethanol, second and third time adds 6 times of amount ethanol, each 1 hour, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste of relative density 1.20 (60 ℃ of heat are surveyed), 60 ℃ of drying under reduced pressure add each 20g of calcium hydrogen phosphate and dextrin respectively, pulverize, mixing, standby; Other gets, and Fructus Phyllanthi is broken into fragment and Fructus Tribuli decocts with water 3 times, adds 12 times of water gagings at every turn, decocted 1 hour, collecting decoction filters, filtrate is concentrated into relative density 1.20 (60 ℃ heat survey), adds ethanol, makes to contain the alcohol amount and reach 70%, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol, 80 ℃ of drying under reduced pressure of concentrated solution are to thick paste, and the adding micropowder silica gel is an amount of, 80 ℃ of drying under reduced pressure are pulverized mixing.Get above-mentioned two kinds of dry extracts, add calcium hydrogen phosphate, micropowder silica gel is an amount of, dextrin is adjusted total amount in right amount, and mixing is made granule promptly.

The preparation of embodiment 3 medicinal tablets of the present invention

1. write out a prescription

Rhizoma Curcumae Longae 290g Radix Berberidis Amurensis 302.5g Fructus Phyllanthi 544.5g Fructus Tribuli 484g Herba Lysimachiae 174g

Adjuvant: an amount of dextrin of an amount of calcium hydrogen phosphate of micropowder silica gel is an amount of

2, method for making

1. above four flavors are got Rhizoma Curcumae Longae, Radix Berberidis Amurensis is ground into coarse powder, adds (85%) 60-95% alcohol reflux (3) 1-3 time, for the first time add (10) 5-15 and doubly measure ethanol, second and third time adds (6) 4-8 and doubly measures ethanol, each (1 hour) 30 minutes-2 hours, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste of relative density about 1.20 (60 ℃ of heat are surveyed), (60 ℃) drying under reduced pressure adds each 20g of calcium hydrogen phosphate and dextrin respectively, pulverizes, mixing, standby; Other gets, and Fructus Phyllanthi is broken into fragment and Fructus Tribuli decocts with water 1-3 time, adds 5-15 (12) times water gaging at every turn, decocted (1 hour) 30 minutes-2 hours, collecting decoction filters, filtrate is concentrated into relative density about 1.20 (60 ℃ heat survey), adds ethanol, makes to contain the alcohol amount and reach (70%) 50-90%, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol, 80 ℃ of drying under reduced pressure of concentrated solution add suitable adjuvant to thick paste, drying under reduced pressure is pulverized mixing.Get above-mentioned two kinds of dry extracts, add an amount of preparation available adjuvant of tablet such as disintegrating agent etc., mixing, the system granule, drying, granulate, coating behind adding lubricant tabletting or the tabletting, promptly.

2. above four flavors are got Rhizoma Curcumae Longae, Radix Berberidis Amurensis by the clear paste that 1. technology obtains after extracting, and add the medical material fine powder after Fructus Phyllanthi and Fructus Tribuli are pulverized, and add after the available proper auxiliary materials of preparation tablet mixes direct compression.

Or: above four flavors, get the clear paste that obtains after Fructus Phyllanthi and Fructus Tribuli are extracted by 1. technology, add the medical material fine powder after Rhizoma Curcumae Longae, Radix Berberidis Amurensis are pulverized, add after the available proper auxiliary materials of preparation tablet mixes direct compression.

The preparation of embodiment 4 medicine oral liquids of the present invention (oral formulations comprises oral liquid)

1. write out a prescription

Rhizoma Curcumae Longae 290g Radix Berberidis Amurensis 302.5g Fructus Phyllanthi 484g Fructus Tribuli 423.5g

Adjuvant: an amount of dextrin of an amount of calcium hydrogen phosphate of micropowder silica gel is an amount of

2, method for making

1. mixture (oral liquid): above four flavors, Rhizoma Curcumae Longae, Radix Berberidis Amurensis, Fructus Phyllanthi and Fructus Tribuli are extracted separately or together with suitable solvent, use the flocculating agent purification and impurity removal, concentrate, and add the used correctives of an amount of general oral formulations, antiseptic etc.) packing, sterilize promptly.

2. oral other liquid preparations:

More than four flavors, Rhizoma Curcumae Longae, Radix Berberidis Amurensis obtain clear paste after alcohol extraction, Fructus Phyllanthi and Fructus Tribuli are carried through water and obtain clear paste, add proper auxiliary materials and mix, and obtain aqueous solution or semi-liquid preparations.

Embodiment 5 drug quality control methods of the present invention

The capsule of getting embodiment 1 preparation carries out qualitative, quantitative control:

1, qualitative control:

(1) get this product 0.25g, add ethanol 15ml, supersound process 15 minutes filters, and filtrate volatilizes, and residue adds ethanol 2ml and makes dissolving, as need testing solution.Other gets berberine hydrochloride, the curcumin reference substance is an amount of, adds ethanol and makes the solution that every 1ml contains 0.5mg and 0.1mg respectively, in contrast product solution.Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw each 1 μ l of above-mentioned three kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with benzene-ethyl acetate-isopropyl alcohol-methanol-water (6: 3: 1.5: 1.5: 0.3) is developing solvent, put in the expansion cylinder of ammonia saturated with vapor, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.

(2) get this product powder 0.5g, add ethanol 30ml, active carbon 0.5g, reflux 30 minutes filters while hot, and filtrate evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other gets the gallic acid reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 2mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 1 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with chloroform-Ethyl formate-formic acid (5: 5: 1) is developing solvent, launch, take out, dry, spray is with 3% ferric chloride alcoholic solution.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.

(3) moisture must not be crossed 9.0% (an appendix IX of Chinese Pharmacopoeia version in 2000 H second method).

Other should meet every regulation relevant under the capsule item (an appendix I of Chinese Pharmacopoeia version in 2000 L).

2, quantitatively control:

Assay: the photograph high performance liquid chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 D) measure.

Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile-0.5% glacial acetic acid solution (volume ratio 45: 55) is a mobile phase; The detection wavelength is 420nm.Theoretical cam curve is calculated with the curcumin peak, should be not less than 3000.

It is an amount of that the curcumin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds ethanol and makes the solution that every 1ml contains 20 μ g, promptly.

The about 0.25g of content under this product content uniformity item is got in the preparation of need testing solution, and accurate the title decides, and puts in the conical flask, and precision adds ethanol 100ml, claim decide weight, supersound process 30 minutes is put coldly, and weight decided in title again, supply the weight that subtracts mistake with ethanol, shake up, filter, promptly.

Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, promptly.

Every of capsule of the present invention contains Rhizoma Curcumae Longae with curcumin (C ₂₁H ₂₀O ₆) meter, must not be less than 2.4mg.

Selecting Rhizoma Curcumae Longae for use is the index of quality control, be because Rhizoma Curcumae Longae is monarch drug in prescription, its usage and consumption direct reaction the drug effect of whole raw material prescription, therefore, determine the lower range of curcumin in the Rhizoma Curcumae Longae, under the condition that is not less than the index consumption, the controllability of the quality of pharmaceutical preparation could improve.

Below prove beneficial effect of the present invention by pharmacodynamics test:

Test example 1 medicine of the present invention is to rat chronic prostatitis model test

1, experiment material

(1) medicine

Medicine capsule of the present invention: by embodiment 1 preparation;

SIWEI JIANGHUANG TANGSAN, SIWEI JIANGHUANG TANGSAN, Qinghai Province Tibetan medicine hospital produces (authentication code: green grass or young crops is defended medicine system word (1998) 024-089), lot number 20011106.Usage and consumption: a 4-5g (calculating by meansigma methods 4.5g) 2 times on the one, is decocted in water for oral dose.The every packed 15g of specification.Decoct 3 times with 5 times of water gagings routinely during test, merge medicinal liquid and be concentrated into 0.3g crude drug/ml and put refrigerator and preserve standby.

Dexamethasone acetate tablets, medicine limited company in Zhejiang produces, specification: 0.75mg/ sheet * 100 slice/bottle, lot number: 020123.Facing the time spent is made into the 3mg/ml medicinal liquid with distilled water.

(2) animal

SD kind rat, male, Mus 11～13 weeks of age, body weight 220--260g, provide by institute of antibiotics, Sichuan Province Experimental Animal Center, meet healthy one-level animal, produce the quality certification: during 99-32 number experiment of the real kinoplaszm in river at herbal pharmacology laboratory animal observation ward of the Chengdu University of Traditional Chinese Medicine (quality certification: No. the 114th, the real kinoplaszm in river) observe and raise.

(3) instrument

TMP-1 upper utensil type electronic balance, balance factory of Hunan Instrument General Factory, device numbers 894, scale division value 1mg.

2, method and result

Choose 60 SD kind rats, male, body weight 220～260g, in Mus 11-13 in age week, behind etherization, sterile working's row median incision of lower abdomen exposes bladder dorsal part prostate (dorsal part leaf), injects the 25% nevus spirit injection 0.2ml that disappears respectively, sews up the incision.Postoperative the 7th day is divided into 6 groups at random by body weight, 10 every group.Press listed medicine of table 1 and dosage, gastric infusion is 1 time/day respectively, successive administration 30 days.In time morning after the last administration, each treated animal takes out prostate, claims to be calculated as follows the prostate organ index after the weight in wet base, and carries out histopathologic examination, the results are shown in Table 1 and table 2.

Table 1 medicine capsule of the present invention is to the influence of chronic prostatitis rat model weight of prostate (x ± SD)

Group	Dosage * number of times (g/kg * d)	Mus number (only)	Prostate
					Weight in wet base (mg)	Organ index (mg/100g body weight)
			Model control group dexamethasone tablet group SIWEI JIANGHUANG TANGSAN group medicine capsule group of the present invention medicine capsule group of the present invention medicine capsule group of the present invention	Distilled water * 30 5mg/kg * 30 3.0 * 30 3.0 * 30 1.5 * 30 0.75 * 30			10 10 10 10 10 10	151.6±16.91 78.2±12.51 126.8±22.01 102.8±23.03 130.6±23.95 138.5±24.07	62.08±6.88 31.78±5.68 *** 51.38±8.99 * 41.69±8.43 ***▲ 52.61±9.93 * 56.24±9.48

Annotate: each administration group and matched group be * P＜0.05 * * * P＜0.001 relatively;

Medicine capsule group of the present invention and SIWEI JIANGHUANG TANGSAN group comparison ▲ P＜0.05

Table 1 shows, 3.0 and 1.5g/kg medicine capsule of the present invention swelling has extremely remarkable and obvious inhibitory action (P＜0.001 and P＜0.05) to chronic prostatitis rat model prostate.When equal clinical dosage, medicine capsule of the present invention is than SIWEI JIANGHUANG TANGSAN effect strong (P＜0.05).

Table 2 medicine capsule of the present invention is to the histological influence of chronic prostatitis rat model prostate pathology (x ± SD)

Group	Dosage * number of times (g/kg * d)	Mus number (n)	Cell infiltration (individual)	Acinus epithelial hyperplasia (individual)	Fibroplasia thickness between acinus (μ m)
						The about composite capsule agent of control group dexamethasone tablet group SIWEI JIANGHUANG TANGSAN the present invention about composite capsule agent the present invention about composite capsule agent the present invention	Equal-volume distilled water * 30 5mg/kg * 30 3.0 * 30 3.0 * 30 1.5 * 30 0.75 * 30	10×5 10×5 10×5 10×5 10×5 10×5	41 12 *** 24 * 25 * 30 36	38 10 *** 25 * 23 * 31 37	63.20±14.12 38.90±12.47 *** 47.30±13.04 * 39.90±9.62 * 51.80±11.48 56.00±12.60

Annotate: (1) each administration group and matched group be * P＜0.05 * * * P＜0.001 relatively;

(2) under 10 * 10 times of mirrors, 5 visuals field of each animal random observation, the Mus number of cell infiltration in matter or the acinus between calculating;

(3) under 10 * 10 times of mirrors, glandular epithelium hypertrophy Mus number is calculated in 5 visuals field of each animal random observation;

(4) each animal is measured minimum spacing between 10 acinuses with micro-mircrometer gauge at random, observes the proliferation of fibrous tissue degree.

Table 2 shows that 3.0g/kg medicine capsule of the present invention has obvious inhibitory action (P＜0.05) to fibroplasia thickness between chronic prostatitis rat model prostatitis cellular infiltration, acinus epithelial hyperplasia and acinus.When equal clinical dosage, this of medicine capsule of the present invention and SIWEI JIANGHUANG TANGSAN acts on no significant difference (P＞0.05).

Above-mentioned test explanation, medicine of the present invention has the effect of treatment chronic prostatitis, and mass action is better than former dosage form (SIWEI JIANGHUANG TANGSAN), illustrate behind the employing process for preparing medicine dosage changing form of the present invention promptly have new drug effect, and drug effect is better than former dosage form.

The 2 medicine in-vitro antibacterial tests of the present invention of test example

1, experiment material

(1) medicine

Medicine capsule of the present invention, embodiment 1 preparation, and the medicine capsule extractum (lot number: 20020401 of the present invention that adopts embodiment 1 to prepare, specification: the 2.9g crude drug/ml), test time-division another name is got 4.24g and 10.24g, after adding 50 ℃ of M-H agar culture medium mixings of 40ml thawing respectively, sucking-off 20ml pastille culture medium is toppled over plate from 40ml, add 20ml in the remaining 20ml pastille culture medium again and do not have the dilution of medicine agar culture medium, behind the mixing again sucking-off 20ml topple over plate, the rest may be inferred, promptly preparing crude drug content with this doubling dilution is 256,128,64,32 ... 0.5mg/ml serial pastille plate stand-by, and crude drug content is 600,300,150,75 ... 1.25mg/ml serial pastille plate stand-by.

SIWEI JIANGHUANG TANGSAN, Qinghai Province Tibetan medicine hospital produces (authentication code: green grass or young crops is defended medicine system word (1998) 024-089), lot number 20011106.Usage and consumption: a 4-5g (calculating by meansigma methods 4.5g) 2 times on the one, is decocted in water for oral dose.The every packed 15g of specification.Decoct 3 times with 5 times of water gagings routinely during test, merge medicinal liquid and be concentrated into 0.3g crude drug/ml and put refrigerator and preserve standby.

Positive control: gentamicin injection liquid, specification: 80,000 units/, lot number: 010801, produce by Chengdu Tong De pharmaceutcal corporation, Ltd.With sterilized water dissolving preparation, being prepared into final concentration is 128,64,32 during test ... 0.25 the serial pastille plate of μ g/ml is stand-by.

Positive control: benzylpenicillin sodium for injection, specification: 800,000 unit/bottles, lot number: 80109316, Huabei Pharmaceutic Co., Ltd produces.With sterilized water dissolving preparation, being prepared into final concentration is 128,64,32 during test ... 0.25 the serial pastille plate of μ g/ml is stand-by.

Positive control: Nysfungin, specification: 500,000 units/sheet, lot number: 011007, Zhejiang Zhenyuan Pharmaceutical Co., Ltd produces.With sterilized water dissolving preparation, being prepared into final concentration is 128,64,32 during test ... 0.25 the serial pastille plate of μ g/ml is stand-by.

(2) antibacterial and fungus

The clinical isolates strain: the test bacterial strain uses therefor is the clinical separation pathogenic bacterium of calendar year 2001 from the collection of area, Sichuan, all strains are being collected isolating unit (Hospital Affiliated To Chengdu Traditional Chinese Medicine Univ clinical laboratory Bacteriology Room and Sichuan Province's dermatopathy and venereal disease study on prevention institute) all after identifying, use after identify again with the API system this chamber again.

Staphylococcus aureus 4 strains, staphylococcus epidermidis 1 strain, escherichia coli 7 strains, Pseudomonas aeruginosa 2 strains, acinetobacter calcoaceticus 3 strains, gonococcus 16 strains, Candida albicans 6 strains, Candida glabrata 2 strains, totally 41 strains.

Standard Quality Control bacterial strain: staphylococcus aureus ATCC25923, escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC27853 are that pharmacological room of Chengdu University of Traditional Chinese Medicine preserves bacterial strain.

(3) culture medium

M-H culture medium: Beijing extensive and profound in meaning star biotechnology responsibility company limited product.The M-H broth bouillon: take by weighing 25g, add the 1000ml distilled water, transfer between pH value to 7.2～7.4, autoclaving, 25 minutes, is used for the drug sensitive test of Grain-positive, negative aerobe by 116 ℃.The M-H solid medium: take by weighing 36.5g, add the 1000ml distilled water, transfer between pH value to 7.2～7.4, autoclaving, 25 minutes, is used for the drug sensitive test of Grain-positive, negative aerobe by 116 ℃.

The improvement sabouraud culture medium: agar powder, peptone are produced by Beijing extensive and profound in meaning star biotechnology responsibility company limited, and glucose (analytical pure) is produced by the self-sufficient and strategically located region, Chongqing fine chemicals factory.Take by weighing peptone 10g respectively, agar powder 20g, glucose 40g adds distilled water 1000ml, mixing, fully dissolving, packing, autoclaving, 116 ℃ 20 minutes, be used for the drug sensitive test of fungus.

Chocolate agar medium: after the MHA culture medium is melted, be chilled to about 50 ℃, add 5-10% defiber Sanguis Leporis seu oryctolagi, after shaking up, put into 80-90 ℃ constant temperature waters, be used for gonococcal drug sensitive test.

2, test method

(1) minimum inhibitory concentration (MIC) is measured

Adopt the agar doubling dilution to measure the minimum inhibitory concentration (MIC) of medicine capsule of the present invention.In the agar plate surface that contains different pharmaceutical concentration, every some bacteria containing amount is about 10 with microbionation ⁵CFU/ml is hatched 18-24 hour observed result for 37 ℃, and being medicine with the least concentration of contained drug in the no bacterial growth plate culture medium the results are shown in Table 3 to the minimum inhibitory concentration (MIC value) of this bacterium.

(2) minimum bactericidal concentration (MBC) is measured

After adopting doubling dilution to measure MIC, to not see that the culture fluid transferred species of bacterial growth is on the agar plate that does not contain medicine, cultivated 18 hours in 37 ℃ again, do not see that the lowest concentration of drug that bacterial growth or antibacterial are lower than 5～10 bacterium colonies is minimum bactericidal concentration (MBC).The results are shown in Table 3.

3, result

Result of the test sees Table 3～table 5.

The antibacterial activity in vitro of table 3 medicine capsule of the present invention

Antibacterial (strain number)	SIWEI JIANGHUANG TANGSAN		Medicine capsule of the present invention		Gentamycin
							MIC (mg/ml)	MBC (mg/ml)	MIC (mg/ml)	MBC (mg/ml)	MIC (μg/ml)	MBC (μg/ml)
	Staphylococcus aureus ATCC25923 staphylococcus aureus 02-1 staphylococcus aureus 02-2 staphylococcus aureus 02-3 staphylococcus aureus 02-4 MRSE 03-1 EHEC ATCC25922 EHEC 01-1 EHEC 01-3 EHEC 01-4 EHEC 01-5 EHEC 01-6 EHEC 01-7 EHEC 01-8 pseudomonas aeruginosa ATCC27853 pseudomonas aeruginosa 04-1 pseudomonas aeruginosa 04-2 acinetobacter calcoaceticus 05-1 acinetobacter calcoaceticus 05-2 acinetobacter calcoaceticus 05-3	＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 75 75 75 75 ＜1.25 75 ＜1.25 ＜1.25 ＜1.25 5 ＜1.25 ＜1.25	128 128 128 128 128 128 128 128 ＞256 ＞256 ＞256 128 ＞256 ＞256 128 128 128 ＞256 128 128	＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 ＜1.25 75 75 75 75 ＜1.25 75 ＜1.25 ＜1.25 ＜1.25 5 ＜1.25 ＜1.25	128 128 128 128 128 128 128 128 ＞256 ＞256 ＞256 128 ＞256 ＞256 128 128 128 ＞256 128 128	＜0.25 128 32 ＞128 32 ＞128 ＜0.25 ＜0.25 ＞128 ＞128 128 ＞128 ＞128 128 4 64 0.5 ＞128 ＜0.25 ＜0.25							32 ＞128 ＞128 ＞128 ＞128 ＞128 16 16 ＞128 ＞128 ＞128 ＞128 ＞128 ＞128 64 ＞128 16 ＞128 8 8

The antibacterial activity in vitro of table 4 medicine capsule of the present invention

Antibacterial (strain number)	SIWEI JIANGHUANG TANGSAN		Medicine capsule of the present invention		The injection penicillin
							MIC (mg/ml)	MBC (mg/ml)	MIC (mg/ml)	MBC (mg/ml)	MIC (μg/ml)	MBC (μg/ml)
	Gonococcus 02-102-1 gonococcus 02-102-2 gonococcus 02-102-3 gonococcus 02-102-4 gonococcus 02-102-5 gonococcus 02-102-6 gonococcus 02-102-7 gonococcus 02-102-8 gonococcus 02-102-9 gonococcus 02-102-11 gonococcus 02-102-12 gonococcus 02-102-13 gonococcus 02-102-14 gonococcus 02-102-15	32 16 16 16 64 1 ＜0.5 64 ＜0.5 ＜0.5 2 8 8 8	＞256 ＞256 ＞256 ＞256 ＞256 256 128 ＞256 64 64 128 ＞256 ＞256 ＞256	16 8 8 8 8 1 ＜0.5 16 ＜0.5 ＜0.5 2 4 4 8	＞256 ＞256 ＞256 ＞256 ＞256 256 128 ＞256 64 64 128 ＞256 ＞256 ＞256	4 2 64 4 64 1 ＜0.25 64 ＜0.25 ＜0.25 ＜0.25 ＜0.25 64 ＜0.25							64 32 128 32 128 8 8 128 4 8 8 8 ＞128 4

The antibacterial activity in vitro of table 5 medicine capsule of the present invention

Antibacterial (strain number)	SIWEI JIANGHUANG TANGSAN		Medicine capsule of the present invention		Nysfungin
							MIC (mg/ml)	MBC (mg/ml)	MIC (mg/ml)	MBC (mg/ml)	MIC (μg/ml)	MBC (μg/ml)
	Candida albicans 02-100-1 Candida albicans 02-100-2 Candida albicans 02-100-3 Candida albicans 02-100-4 Candida albicans 02-100-5 Candida albicans 02-100-6 Candida glabrata 02-101-1 Candida glabrata 02-101-2	16 16 16 32 16 4 16 16	＞256 ＞256 ＞256 ＞256 ＞256 ＞256 ＞256 ＞256	8 8 8 16 16 4 16 8	＞256 ＞256 ＞256 ＞256 ＞256 ＞256 ＞256 ＞256	4 8 4 16 2 2 ＞128 16							32 128 64 128 32 32 ＞128 128

Table 3 shows, medicine capsule of the present invention is external all to have certain antibacterial vigor to the common Grain-positive of clinical separation, negative pathogenic bacterium and fungus, and medicine capsule of the present invention is＜1.25mg crude drug/ml the MlC value scope of institute's ensaying Staphylococcus aureus, staphylococcus epidermidis; MIC value scope to examination escherichia coli, Pseudomonas aeruginosa and acinetobacter calcoaceticus is respectively＜1.25～75mg crude drug/ml,＜1.25mg crude drug/ml and＜1.25～5mg crude drug/ml, be＜0.5～16mg crude drug/ml to gonococcal MIC value scope.Medicine capsule of the present invention has certain antibacterial vigor to the clinical common fungus of try, and medicine capsule of the present invention is 4～16mg crude drug/ml to the oidiomycetic MIC value of white scope, is 8～16mg crude drug/ml to the MIC value scope of Candida glabrata.But bactericidal action is not strong.Medicine capsule of the present invention is stronger to gonococcus and Candida albicans bacteriostasis than SIWEI JIANGHUANG TANGSAN.

Test example 3 medicines of the present invention are tested rat aseptic urethral meatitis

1, experiment material

(1) medicine

Medicine capsule of the present invention and SIWEI JIANGHUANG TANGSAN are referring to test example 1 described medicine.

Amounting to of table 6 medicine capsule of the present invention and capsular compound method and dosage

Animal	Drug level (g/ml)	Administration volume (ml/kg)	Dosage (g/kg)	The multiple (doubly) that is equivalent to clinical dosage
					Big mice	0.3 0.15 0.075	10 10 10	3.0 1.5 0.75	20 10 5

Dexamethasone acetate tablets, medicine limited company in Zhejiang produces, specification: 0.75mg/ sheet * 100 slice/bottle, lot number: 000505.Facing the time spent is made into the 3mg/ml medicinal liquid with distilled water.

(2) animal

SD kind rat, male, in Mus 12～14 weeks of age, body weight 190--230g is provided by institute of antibiotics, Sichuan Province Experimental Animal Center, meets healthy one-level animal, produces the quality certification: the real kinoplaszm in river 99-30 number.During experiment at herbal pharmacology laboratory animal observation ward of the Chengdu University of Traditional Chinese Medicine (quality certification: No. the 114th, the real kinoplaszm in river) observe and raise.

(3) instrument

TMP-1 upper utensil type electronic balance, balance factory of Hunan Instrument General Factory, device numbers 894, scale division value 1mg.

(4) reagent

Dimethylbenzene, the AR level, Medical Depot chemical reagents corporation in Guangzhou produces, specification 500ml/ bottle, lot number 991014.

2, method and result

Choose 70 SD kind rats, male, body weight 200～230g in Mus 12-14 in age week, is divided into 6 groups by body weight, 10 every group at random.Each treated animal is applied to the outer penis urethral orifice top of rat with dimethylbenzene 10 μ l and causes inflammation, behind the 15min, presses listed medicine of table 7 and dosage, and gastric infusion once respectively.60min after the administration, the sacrificed by decapitation rat is cut penis from rat penis urethral orifice top to root 4mm, and weigh (swelling degree) the results are shown in Table 7.

The influence of rat aseptic urethral meatitis due to the table 7 medicine capsule xylol of the present invention (x ± SD)

Group	Dosage * number of times (g/kg * c)	Mus number (only)	Swelling degree (mg)
				Normal control group model matched group dexamethasone tablet group SIWEI JIANGHUANG TANGSAN group medicine capsule group of the present invention	Equal-volume distilled water * 1 equal-volume distilled water * 1 30mg/kg * 1 3.0 * 1 3.0 * 1 1.5 * 1 0.75 * 1	10 10 10 10 10 10 10	65.60±13.11 101.80±15.02 ▲▲▲ 71.80±13.31 *** 85.80±12.99 * 84.20±13.97 * 89.00±17.22 95.40±15.04

Annotate: model control group and the comparison of normal control group ▲ ▲ ▲ P＜0.001;

Each administration group and model control group be * P＜0.05 * * * P＜0.001 relatively

The swelling of rat urethral orifice inflammatory has obvious inhibitory action (P＜0.05) due to table 7 demonstration, 3.0g/kg medicine capsule xylol of the present invention.

By above-mentioned pharmacodynamics test as can be known, swelling has extremely remarkable and obvious inhibitory action (P＜0.001 and P＜0.05) to chronic prostatitis rat model prostate for (1) 3.0g/kg of medicine of the present invention and 1.5g/kg medicine capsule of the present invention.When equal clinical dosage, medicine capsule of the present invention suppresses chronic prostatitis rat model prostate swelling effect strong (P＜0.05) than SIWEI JIANGHUANG TANGSAN.3.0g/kg medicine capsule of the present invention has obvious inhibitory action (P＜0.05) to fibroplasia thickness between chronic prostatitis rat model prostatitis cellular infiltration, acinus epithelial hyperplasia and acinus.(2) the in-vitro antibacterial test shows: medicine capsule of the present invention is external all to have certain antibacterial vigor to the common Grain-positive of clinical separation, negative pathogenic bacterium and fungus, and medicine capsule of the present invention is＜1.25mg crude drug/ml the MIC value scope of institute's ensaying Staphylococcus aureus, staphylococcus epidermidis; MIC value scope to examination escherichia coli, Pseudomonas aeruginosa and acinetobacter calcoaceticus is respectively＜1.25～75mg crude drug/ml,＜1.25mg crude drug/ml and＜1.25～5mg crude drug/ml, be＜0.5～16mg crude drug/ml to gonococcal MIC value scope.Medicine capsule of the present invention has certain antibacterial vigor to the clinical common fungus of try, and medicine capsule of the present invention is 4～16mg crude drug/ml to the oidiomycetic MIC value of white scope, is 8～16mg crude drug/ml to the MIC value scope of Candida glabrata.But bactericidal action is not strong.Medicine capsule of the present invention than SIWEI JIANGHUANG TANGSAN to gonococcus and Candida albicans bacteriostasis stronger (P＜0.05).(3) swelling of rat urethral orifice inflammatory has obvious inhibitory action (P＜0.05) due to the 3.0g/kg medicine capsule xylol of the present invention.

Above-mentioned test proves that fully medicine of the present invention has antibiotic, antiinflammatory, eases pain, alleviates urethra inflammation and chronic prostatitis syndrome, microcirculation improvement and hemorheological property effect.Pharmaceutical composition of the present invention changes by technology, dosage form, aspect antibiotic, sterilization, aspect the treatment urethritis, except the effect that keeps former dosage form, has improved quality standard, increases qualitative, quantitative identification method, controllability raising, preparation stabilization; Increased new indication, treatment chronic prostatitis determined curative effect.

Claims (10)

1, a kind of by containing the purposes of pharmaceutical composition in the medicine of preparation treatment chronic prostatitis that the following weight proportion raw material is prepared from:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis.

2, purposes according to claim 1 is characterized in that: it is to be prepared from by the following weight proportion raw material:

5 parts in Rhizoma Curcumae Longae, 4 parts of Radix Berberidis Amurensis, 8 parts of Fructus Phyllanthis, 8 parts of Fructus Tribulis.

3, a kind ofly be: the pharmaceutical composition of the treatment chronic prostatitis that the feedstock production of 4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis forms by containing weight proportion.

4, the pharmaceutical composition of treatment chronic prostatitis according to claim 3 is characterized in that: it is the medicament that is prepared from by the following weight proportion raw material:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis.

5, the pharmaceutical composition of treatment chronic prostatitis according to claim 4 is characterized in that: it is the medicament that is prepared from by the following weight proportion raw material:

5 parts in Rhizoma Curcumae Longae, 4 parts of Radix Berberidis Amurensis, 8 parts of Fructus Phyllanthis, 8 parts of Fructus Tribulis.

6, according to the pharmaceutical composition of claim 4 or 5 described treatment chronic prostatitiss, it is characterized in that: it is that water extract by the ethanol extraction of Rhizoma Curcumae Longae, Radix Berberidis Amurensis and Fructus Phyllanthi, Fructus Tribuli is mixed into active component, adds the medicament that acceptable accessories or complementary composition are prepared from.

7, the pharmaceutical composition of treatment chronic prostatitis according to claim 6 is characterized in that: described medicament is: pill, powder, tablet, dispersible tablet, capsule, hard capsule, soft capsule, granule, oral liquid.

8, the pharmaceutical composition of treatment chronic prostatitis according to claim 7 is characterized in that: every capsules contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 2.4mg; Every in tablet contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 0.6mg; Every of pill contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 0.12mg; Every 10g powder contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 1.2mg; Every 10ml oral liquid contains Rhizoma Curcumae Longae with curcumin C ₂₁H ₂₀O ₆Meter must not be less than 1.2mg.

9, a kind of method for preparing the prostatitic pharmaceutical composition of each described treatment of claim 3-8, it comprises the steps:

A, take by weighing and contain the following weight proportion raw material:

4～6 parts in Rhizoma Curcumae Longae, 3～5 parts of Radix Berberidis Amurensis, 7～9 parts of Fructus Phyllanthis, 7～9 parts of Fructus Tribulis;

B, Rhizoma Curcumae Longae, Radix Berberidis Amurensis ethanol extraction, concentration of alcohol are 60%～95%, reclaim ethanol, get extracting solution;

C, Fructus Phyllanthi, Fructus Tribuli are adopted water extract, ethanol is refining, and concentration of alcohol 50～90% reclaims ethanol, extracting solution;

D, b step gained extracting solution is mixed with c step extracting solution, add acceptable accessories or complementary composition, be prepared into preparation pharmaceutically commonly used.

10, the purposes of the described pharmaceutical composition of claim 3 in the medicine of preparation treatment urethritis.